-

Forbes Names Zoetis One of America’s Best Midsize Employers

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS), the global leader in animal health, today announced that it has been named one of America’s Best Midsize Employers by Forbes Magazine for the fifth time.

“At Zoetis, our colleagues drive our success and shape our reputation as a top employer,” said Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Global Operations. “We continue to build a diverse and inclusive culture - based on our Core Beliefs – where everyone can thrive, both personally and professionally. We are proud to consistently be recognized by Forbes as one of America’s Best Midsize Employers, and we thank our colleagues for recommending Zoetis as a great place to work.”

Forbes determined its America’s Best Employers list based on an independent survey among a sample of 50,000 American employees working for companies with at least 1,000 people in their U.S. operations. The willingness to recommend one's own employer was used as the most important factor in the assessment. The employees were consulted anonymously through online access panels which allowed them to express their opinions. Visit Forbes.com for more details about the list of America’s Best Midsize Employers.

Award-Winning Culture

Zoetis has consistently been recognized as a great place to work. The company has been named among the Top Companies for Working Mothers for the past seven years, as well as a Top Company for Executive Women for three years in a row. Most recently, Zoetis received a score of 100 percent on the Human Rights Campaign Foundation’s 2021 Corporate Equality Index (CEI), the nation’s foremost benchmarking survey and report measuring corporate policies and practices related to LGBTQ workplace equality.

Learn More

For more information about Zoetis, including career opportunities, our commitment to Diversity, Equity and Inclusion, and our award-winning culture, visit https://careers.zoetis.com/.

About Zoetis

Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses.

Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2019, the company generated annual revenue of $6.3 billion with approximately 10,600 employees. For more information, visit www.zoetis.com.

ZTS-COR

Contacts

Media Contacts:
Bill Price
1-973-443-2742 (o)
william.price@zoetis.com

Kristen Seely
1-973-443-2777 (o)
kristen.seely@zoetis.com

Zoetis Inc.

NYSE:ZTS

Release Summary
Zoetis has been named one of America’s Best Midsize Employers by Forbes Magazine for the fifth time.
Release Versions
$Cashtags

Contacts

Media Contacts:
Bill Price
1-973-443-2742 (o)
william.price@zoetis.com

Kristen Seely
1-973-443-2777 (o)
kristen.seely@zoetis.com

Social Media Profiles
More News From Zoetis Inc.

Zoetis Receives Health Canada Approval for Portela™(relfovetmab injection) to Alleviate Pain Associated with Osteoarthritis in Cats

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. today announced that Health Canada has approved Portela™ (relfovetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in cats. Designed to provide three months of OA pain relief with a single injection, Portela targets anti-nerve growth factor (NGF), which is a key mediator of OA pain and inflammation. In a nine-month field trial in Europe, Portela demonstrated effectiveness in alleviating OA pain and was found to be well...

Zoetis Highlights R&D Leadership and Long-Term Growth Opportunity at Innovation Webcast

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS), the world’s leading animal health company, will host an Innovation Webcast today at 8:30 a.m. ET to provide an update on its proven innovation model, robust and diversified R&D pipeline, and upcoming growth catalysts as the company continues pioneering the future of animal health. “The pace of animal health innovation is accelerating alongside a growing appreciation for the essential role animals play in our lives and communities....

Zoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Lenivia® (izenivetmab) for the reduction of pain associated with osteoarthritis (OA) in dogs. Lenivia is a new antibody therapy that reduces OA pain in dogs for three months with one injection through its novel binding properties to nerve growth factor (NGF), recognized as an important mediator of pain and inflammation. Lenivia is built on a decade of s...
Back to Newsroom